Regulation of human basophil activation. II. Histamine release is potentiated by K+ efflux and inhibited by Na+ influx.
Na+ and K+ are the major extra- and intracellular cations, respectively. We have thus studied the role of these ions on human basophil histamine release by modifying their transmembrane gradients or by increasing membrane ion fluxes using ionophores. 1) When external Na+ (reduced to 4 mM) was replaced by the nonpermeating Na+ substitute N-methyl-D-glucamine, the release of histamine was enhanced in 2 mM Ca2+ (from 37.5 +/- 8.0% in 140 mM Na+ to 68.5 +/- 9.1% in low Na+) and became possible in the presence of low Ca2+ (at 1 microM Ca2+: from 0.6 +/- 0.7% in 140 mM Na+ to 36.2 +/- 8.0% in low Na+); moreover, in low Na+, the release of histamine became partly independent on Ca2+ influx. 2) Increasing the Na+ influx with the cation channel-forming gramicidin D inhibited the release of histamine by 33.2 +/- 13.6% (n = 6) in an external Na(+)-dependent manner. 3) Decreasing K+ efflux using K+ channel blockers (4-aminopyridine, quinine, sparteine) inhibited histamine release in a dose-response manner. 4) The K+ ionophore valinomycin, which increases K+ efflux, slightly enhanced IgE-mediated histamine release when used alone, whereas it potentiated the release of histamine from leukocytes previously treated with 4-aminopyridine by 57.0 +/- 18.6% (n = 7). 5) Decreasing K+ efflux by increasing external K+ inhibited IgE-mediated release in a similar manner as Na+ did. The inhibitory effects of Na+ and high K+ were not additive, thus suggesting that both cations inhibited the release by a common mechanism. In conclusion 1) our data evidence that histamine release from human basophils is inhibited by Na+ influx and potentiated by K+ efflux; 2) they suggest that K+ channels are present on the basophil membrane and that Na+ and K+ fluxes act on histamine release most probably via modulation of membrane potential.
Beauvais
F
F
INSERM U200, Université Paris-Sud, Clamart, France.
Shimahara
T
T
Inoue
I
I
Hieblot
C
C
Burtin
C
C
Benveniste
J
J
D015761:4-Aminopyridine / Q000494:pharmacology; D001491:Basophils / Q000502:physiology*; D002118:Calcium / Q000502:physiology; D004533:Egtazic Acid / Q000494:pharmacology; D006096:Gramicidin / Q000494:pharmacology; D006636:Histamine Release; D006801:Humans; D007073:Immunoglobulin E / Q000502:physiology*; D066298:In Vitro Techniques; D011188:Potassium / Q000502:physiology*; D015221:Potassium Channels / Q000187:drug effects; D011802:Quinidine / Q000494:pharmacology; D012964:Sodium / Q000502:physiology*; D013034:Sparteine / Q000494:pharmacology; D014634:Valinomycin / Q000494:pharmacology
D015221:Potassium Channels; D006096:Gramicidin; D014634:Valinomycin; D013034:Sparteine; D007073:Immunoglobulin E; D004533:Egtazic Acid; D012964:Sodium; D015761:4-Aminopyridine; D011802:Quinidine; D011188:Potassium; D002118:Calcium